What is ORIC's market cap?

$940.13M, based on the Nov 2 close of $9.07.

Does Oric Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ORIC is sold short?

15.4M shares, 25.5% of float, as of Oct 15, 2026.

What sector is ORIC in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ORICHealthcarePharmaceuticals

Oric Pharmaceuticals, Inc. Common Stock (ORIC)

$9.07−1.84%

Close Nov 2, 2026 · split-adjusted

Oct 30, 2026$9.24▼ 27.19% in range

Nov 3, 2025Low $7.47 · High $14.65Oct 30, 2026

What changed · written from our data

As of Nov 2, 2026

Oric Pharmaceuticals closed at $9.07 on Nov 2, down 1.84%, 38.1% below its 52-week closing high. Volume of 1.9M shares was 1.00× its 20-day average (close to normal).

Split-adjusted performance: -25.7% over one month, -5.8% over six months, -32.0% over one year.

Short interest was 15.4M shares at the Oct 15 settlement, down 5.5% from the prior report (25.5% of float, 10.5 days to cover).

Market cap$940.1M103.7M shares

Revenue · quarter$0.00—

Diluted EPS$-0.38—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range7.47 – 14.65−38.1% from high

Volume1.9M1.00× 20-day avg

Volatility · 60d93.0%Annualised

Short % of float25.5%10.5 days to cover

Net cash$264.8MCash $264.8M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.3%1M −25.7%3M −32.7%6M −5.8%YTD +10.9%1Y −32.0%3Y +40.0%5Y −39.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum68

Revenue growth—

Net margin—

Value (low P/E)—

Size70

Industry medians: 6-month return −25.1%, revenue growth +6.4%, net margin −36.2%, P/E 15.8×.

Short interest

Details →

Shares short15.4M−5.5% vs prior

Days to cover10.5Settled Oct 15

% of float25.5%

Short vol. 10d45.1%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ORICOric Pharmaceuticals	$9.07	−1.84%	−5.8%	—	—	—	$940.1M
RIGLRigel Pharmaceuticals Inc. (New)	$50.53	−1.52%	+71.1%	−22.6%	22.0%	2.9	$943.9M	Compare
SVRASavara	$4.73	−1.87%	−10.8%	—	—	—	$971.8M	Compare
MLTXMoonLake Immunotherapeutics	$11.47	−2.63%	−34.7%	—	—	—	$976.2M	Compare
LTGOLatigo Biotherapeutics	$13.51	−3.15%	—	—	—	—	$895.7M	Compare
OBXObsidian Therapeutics	$14.43	−2.43%	—	—	—	—	$891.4M	Compare
JBIOJade Biosciences	$13.93	−0.92%	−43.2%	—	—	—	$885.9M	Compare
KURAKura Oncology	$9.79	−4.58%	+5.8%	+36.5%	−327.3%	—	$870.9M	Compare
ANROAlto Neuroscience	$22.19	−1.81%	−11.9%	—	—	—	$870.8M	Compare

News about Oric Pharmaceuticals

All news →

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 TrialGlobeNewswire Inc. · Oct 23, 2026▲ Positive ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026GlobeNewswire Inc. · Oct 23, 2026▲ Positive ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Aug 7, 2026Neutral INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICGlobeNewswire Inc. · May 12, 2026▼ Negative ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?Benzinga · Apr 1, 2026▼ Negative

Quick answers

What does Oric Pharmaceuticals do?: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies.
What is ORIC's market cap?: $940.13M, based on the Nov 2 close of $9.07.
Does Oric Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ORIC is sold short?: 15.4M shares, 25.5% of float, as of Oct 15, 2026.
What sector is ORIC in?: Healthcare, in the Pharmaceuticals industry.

About Oric Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

HQ: South San Francisco, CA111 employeesListed Apr 24, 2020oricpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology